Hepatocellular (HCC) is the most common type of primary liver cancer and the fourth most common cause of cancer-related deaths globally. Although most cases of HCC were historically attributed to underlying chronic viral hepatitis, nonalcoholic fatty liver disease is projected to become the most common risk factor for HCC with the rising prevalence of obesity and diabetes mellitus and increasing availability of effective treatments for hepatitis B and C infection. Although patients with viral and nonviral HCC seem to have similar overall prognosis, prior data have suggested possible differential efficacy of systemic therapies by liver disease etiology. For example, sorafenib was shown to have greater efficacy in patients with chronic hepatitis C infection than other etiologies. The aim of our descriptive study was to report the effectiveness of lenvatinib in a real-world cohort of patients with nonalcoholic steatohepatitis (NASH)-related HCC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2021.11.020DOI Listing

Publication Analysis

Top Keywords

effectiveness lenvatinib
8
patients nonalcoholic
8
nonalcoholic steatohepatitis
8
liver disease
8
hepatitis infection
8
hcc
5
real-world effectiveness
4
lenvatinib hepatocellular
4
hepatocellular carcinoma
4
patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!